Literature DB >> 7275977

5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity.

D W Kufe, P P Major.   

Abstract

We demonstrate a highly significant relationship (p less than 0.0001) between the incorporation of 5-flourouracil in total cellular RNA and loss of clonogenic survival of the human MCF-7 breast carcinoma cell line. The extent of 5-fluorouracil incorporation in RNA is concentration- and time-dependent. Identical results are obtained in experiments employing thymidine to bypass the block of thymidylate synthetase and reverse inhibition of DNA synthesis. These studies suggest that the incorporation of 5-fluorouracil in RNA is the major mechanism of cytotoxic action in this human cell line.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7275977

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


  40 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  Synthesis of novel spin-labeled derivatives of 5-FU as potential antineoplastic agents.

Authors:  Liu Yang; Mei-Juan Wang; Zhi-Jun Zhang; Susan L Morris-Natschke; Masuo Goto; Jing Tian; Ying-Qian Liu; Chih-Ya Wang; Xuan Tian; Xiao-Ming Yang; Kuo-Hsiung Lee
Journal:  Med Chem Res       Date:  2014-07       Impact factor: 1.965

3.  Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.

Authors:  M Iigo; M Miwa; H Ishitsuka; K Nitta
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  The effect of structural modifications of 5-fluorouracil derivatives on their transport and biodegradation by isolated rat jejunum.

Authors:  L Novotný; H Farghali; I Janků; J Beránek
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  All-Atom Molecular Dynamics Reveals Mechanism of Zinc Complexation with Therapeutic F10.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  J Phys Chem B       Date:  2016-09-21       Impact factor: 2.991

6.  Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).

Authors:  Patricia M LoRusso; Sucharu Prakash; Antoinette Wozniak; Lawrence Flaherty; Mark Zalupski; Anthony Shields; Howard Sands; Ralph Parchment; Bhaskara Jasti
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

7.  Incorporation of pyrimidines and 5-fluoropyrimidines into normal tissues and an adenocarcinoma transplanted into the liver in rat.

Authors:  P I Christensson; C Erichsen; P E Jönsson; U Stenram
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

8.  Chromosome segregation and organization are targets of 5'-Fluorouracil in eukaryotic cells.

Authors:  Laura Mojardín; Javier Botet; Sergio Moreno; Margarita Salas
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2'-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver.

Authors:  M Berne; B Gustavsson; O Almersjö; C P Spears; J Waldenström
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells.

Authors:  P P Major; E M Egan; L Sargent; D W Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.